CN105658222A - 游离碱晶体 - Google Patents

游离碱晶体 Download PDF

Info

Publication number
CN105658222A
CN105658222A CN201480046150.4A CN201480046150A CN105658222A CN 105658222 A CN105658222 A CN 105658222A CN 201480046150 A CN201480046150 A CN 201480046150A CN 105658222 A CN105658222 A CN 105658222A
Authority
CN
China
Prior art keywords
methyl
crystal
phenyl
crystals
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480046150.4A
Other languages
English (en)
Chinese (zh)
Inventor
安倍隆
G·巴克顿
R·戴维斯
M·霍珀
P·李
丸山秀明
高须正浩
L·P·文诺格勒
山本裕平
山下弘典
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Priority to CN202110144523.3A priority Critical patent/CN112851683A/zh
Priority to CN201910526464.9A priority patent/CN110498800A/zh
Publication of CN105658222A publication Critical patent/CN105658222A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201480046150.4A 2013-06-21 2014-06-20 游离碱晶体 Pending CN105658222A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202110144523.3A CN112851683A (zh) 2013-06-21 2014-06-20 游离碱晶体
CN201910526464.9A CN110498800A (zh) 2013-06-21 2014-06-20 游离碱晶体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361838105P 2013-06-21 2013-06-21
US61/838,105 2013-06-21
US201361919424P 2013-12-20 2013-12-20
US61/919,424 2013-12-20
PCT/US2014/043422 WO2014205354A2 (en) 2013-06-21 2014-06-20 Free base crystals

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201910526464.9A Division CN110498800A (zh) 2013-06-21 2014-06-20 游离碱晶体
CN202110144523.3A Division CN112851683A (zh) 2013-06-21 2014-06-20 游离碱晶体

Publications (1)

Publication Number Publication Date
CN105658222A true CN105658222A (zh) 2016-06-08

Family

ID=52105535

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201480046150.4A Pending CN105658222A (zh) 2013-06-21 2014-06-20 游离碱晶体
CN201910526464.9A Pending CN110498800A (zh) 2013-06-21 2014-06-20 游离碱晶体
CN202110144523.3A Pending CN112851683A (zh) 2013-06-21 2014-06-20 游离碱晶体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201910526464.9A Pending CN110498800A (zh) 2013-06-21 2014-06-20 游离碱晶体
CN202110144523.3A Pending CN112851683A (zh) 2013-06-21 2014-06-20 游离碱晶体

Country Status (13)

Country Link
US (1) US9630971B2 (https=)
EP (2) EP3010509B1 (https=)
JP (2) JP6865036B2 (https=)
KR (2) KR102430126B1 (https=)
CN (3) CN105658222A (https=)
AU (1) AU2014284224B2 (https=)
BR (1) BR112015032132B1 (https=)
CA (1) CA2916393C (https=)
ES (1) ES2894770T3 (https=)
IL (2) IL267331B2 (https=)
MX (2) MX2015017972A (https=)
RU (1) RU2675851C2 (https=)
WO (1) WO2014205354A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
AR091507A1 (es) * 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
CN105658222A (zh) 2013-06-21 2016-06-08 细胞内治疗公司 游离碱晶体
EP4025202A4 (en) 2019-09-03 2023-08-02 Intra-Cellular Therapies, Inc. NOVEL CONNECTIONS
WO2021226407A1 (en) * 2020-05-06 2021-11-11 Intra-Cellular Therapies, Inc. Free base crystals
EP4188353A4 (en) * 2020-07-26 2024-07-03 Intra-Cellular Therapies, Inc. Novel uses
EP4395767A4 (en) * 2021-09-03 2025-07-23 Intra Cellular Therapies Inc CO-CRYSTALS
EP4469052A4 (en) * 2022-01-27 2026-02-11 Intra Cellular Therapies Inc NEW COMPOSITIONS
WO2023147603A2 (en) * 2022-01-31 2023-08-03 Intra-Cellular Therapies, Inc. Salt crystals
WO2023233410A1 (en) * 2022-06-02 2023-12-07 Biosight Ltd. Crystalline form of aspacytarabine intermediate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970444A (zh) * 2007-12-06 2011-02-09 细胞内治疗公司 有机化合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9412571D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
US5471001A (en) * 1994-12-15 1995-11-28 E. I. Du Pont De Nemours And Company Crystallization of adipic acid
GB9624615D0 (en) 1996-11-26 1997-01-15 Zeneca Ltd Chrystallisation process
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
TWI305530B (en) * 2002-02-08 2009-01-21 Ono Pharmaceutical Co Piperidine derivative compound and pharmaceuticals containing same as active ingredient
EP1613747A1 (en) 2003-03-31 2006-01-11 Pfizer Products Inc. Crystal structure of 3 ,5 -cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof
CA2536251C (en) 2003-09-02 2009-08-04 Merck & Co., Inc. Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
CA2580129A1 (en) * 2004-09-27 2006-04-06 Acadia Pharmaceuticals Inc. Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation
US8273750B2 (en) 2005-06-06 2012-09-25 Takeda Pharmaceutical Company Limited Organic compounds
JP2010509399A (ja) 2006-11-13 2010-03-25 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
US9006258B2 (en) 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
US20120070443A1 (en) * 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
MX2011005936A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
JP5989993B2 (ja) 2008-12-06 2016-09-07 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
CN102231953A (zh) 2008-12-06 2011-11-02 细胞内治疗公司 有机化合物
JP2012518685A (ja) 2009-02-25 2012-08-16 イントラ−セルラー・セラピーズ・インコーポレイテッド 眼障害のためのｐｄｅ１阻害剤
US9468637B2 (en) * 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
JP2013507360A (ja) 2009-10-08 2013-03-04 イントラ−セルラー・セラピーズ・インコーポレイテッド ホスホジエステラーゼ１−標的トレーサーおよび方法
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
AR091507A1 (es) * 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
CN105658222A (zh) 2013-06-21 2016-06-08 细胞内治疗公司 游离碱晶体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970444A (zh) * 2007-12-06 2011-02-09 细胞内治疗公司 有机化合物

Also Published As

Publication number Publication date
BR112015032132A2 (pt) 2017-07-25
KR20210122890A (ko) 2021-10-12
IL267331B2 (en) 2024-12-01
IL243269A0 (en) 2016-02-29
HK1223848A1 (zh) 2017-08-11
JP2019189618A (ja) 2019-10-31
MX2015017972A (es) 2016-10-28
US20160145261A1 (en) 2016-05-26
WO2014205354A2 (en) 2014-12-24
KR20160040522A (ko) 2016-04-14
IL267331B1 (en) 2024-08-01
CA2916393C (en) 2022-03-22
MX2020001628A (es) 2020-07-13
WO2014205354A3 (en) 2015-05-28
AU2014284224A1 (en) 2016-02-11
RU2675851C2 (ru) 2018-12-25
AU2014284224B2 (en) 2019-08-01
EP3010509A2 (en) 2016-04-27
CA2916393A1 (en) 2014-12-24
KR102430126B1 (ko) 2022-08-05
IL243269B (en) 2019-06-30
JP6865036B2 (ja) 2021-04-28
RU2016101630A (ru) 2017-07-26
ES2894770T3 (es) 2022-02-15
IL267331A (en) 2019-08-29
BR112015032132B1 (pt) 2022-03-15
US9630971B2 (en) 2017-04-25
CN110498800A (zh) 2019-11-26
EP3010509B1 (en) 2021-07-28
JP2016523258A (ja) 2016-08-08
CN112851683A (zh) 2021-05-28
EP3702358A1 (en) 2020-09-02
RU2016101630A3 (https=) 2018-03-21
EP3010509A4 (en) 2016-11-23

Similar Documents

Publication Publication Date Title
CN105658222A (zh) 游离碱晶体
CN104602695B (zh) 盐晶体
CN108699063A (zh) 一种芦可替尼的合成工艺
CN114423755A (zh) 用于合成缬苯那嗪的方法
US12435093B2 (en) Free base crystals
HK40036801A (en) Process for preparing salts of a known pde1 inhibitor
CN117105931A (zh) 一种制备吡啶并嘧啶类化合物的方法及其中间体
JP2025505577A (ja) （６ａ，１２ａ）－１７－アミノ－１２－メチル－６，１５－ビス（トリフルオロメチル）－１３，１９－ジオキサ－３，４，１８－トリアザトリシクロ［１２．３．１．１２，５］ノナデカ－１（１８），２，４，１４，１６－ペンタエン－６－オールの調製方法及び結晶形態
HK1223848B (en) Free base crystals
CN102898397B (zh) (4aR,10bR)-3,4,4a,5,6,10b-六氢-2H-萘并[1,2-b][1,4]噁嗪-9-醇类物质及其盐酸盐合成方法
EP2847195A1 (en) Form 2 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
HK40090878A (zh) 用於制备1-甲基-6-[6-r2-5-甲基-8-(甲基氨基)-4-[(3as，6as)-5-甲基-2，3，3a，4，6，6a-六氢吡咯并[2，3-c]吡咯-1-基]-9h-吡啶并[2，3-b]吲哚-3-基]-4-氧代-1，8-萘啶-3-甲酸盐酸盐的方法
HK40125773A (zh) Iap拮抗剂化合物和中间体及其合成方法
HK1247191A1 (en) Salt crystals
WO2013170241A1 (en) Polymorphs of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolol[4,3b]pyridazine
CN102439010A (zh) 稠合三环磺酰胺的制备方法
HK1223613B (zh) 用於制备取代的5-氟-1h-吡唑并吡啶类化合物的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160608

RJ01 Rejection of invention patent application after publication